Sykehusinnkjøp HF 916879067 Postboks 40 Vadsø 9811 Bjørnar Nordbotten bjnor@sykehusinnkjop.no https://permalink.mercell.com/81028295.aspx http://www.sykehusinnkjop.no/ Procurement of lighting apparatuses for pathogenetic reduction of blood components — St Olavs Hospital 2018/101 St Olavs Hospital HF has decided to enter into a procurement contract with Cerus Europe BV for the procurement of 2 “lighting apparatuses for pathogenetic reduction of blood components”, with the necessary instrument specific consumables. 1650000.00 Trondheim. St Olavs Hospital HF currently has 2 lighting apparatuses for pathogenetic reduction of blood components. The apparatuses were procured from Baxter in 2003 and are nearing the end of their lifetime. Cerus has taken over as a dealer of the Intercept system, which shall now be renewed. St Olavs Hospital would like to make a direct procurement of new lighting apparatuses, due to the comprehensive knock-on effects and major costs involved with a change of supplier. Furthermore, new technology is expected in the market in the new lighting apparatuses' lifetime, which will enable pathogenetic reduction of full blood, so it would, thus, be natural to hold an open tender contest next time. A cost estimate shows that the costs of changing method will amount to approx. 1 330 000 NOK. The validation period of a new concept would be expected to last for 30 weeks. After studying and comparing scientific articles and experience reports for the 2 known methods, St Olavs Hospital is of the opinion that the existing method is the best method for St Olavs Hospital's production and needs. St Olavs Hospital HF currently has 2 lighting apparatuses for pathogenetic reduction of blood components. The apparatuses were procured from Baxter in 2003 and are nearing the end of their lifetime. Cerus has taken over as a dealer of the Intercept system, which shall now be renewed. St Olavs Hospital would like to make a direct procurement of new lighting apparatuses, due to the comprehensive knock-on effects and major costs involved with a change of supplier. Furthermore, new technology is expected in the market in the new lighting apparatuses' lifetime, which will enable pathogenetic reduction of full blood, so it would, thus, be natural to hold an open tender contest next time. A cost estimate shows that the costs of changing method will amount to approx. 1 330 000 NOK. The validation period of a new concept would be expected to last for 30 weeks. After studying and comparing scientific articles and experience reports for the 2 known methods, St Olavs Hospital is of the opinion that the existing method is the best method for St Olavs Hospital´s production and needs. 2018/101 2018/101 Lighting apparatuses for pathogenetic reduction of blood components 2018-04-03 Cerus Europe BV NL8156.23.938 B01 Stationsstraat 79-D Amersfoort 3811 MH 1650000.00 Klagenemnda for offentlige anskaffelser Bergen https://kofa.no/ 2018-04-04
See tender at TED: http://ted.europa.eu/udl?uri=TED:NOTICE:148121-2018:TEXT:EN:HTML